24 January 2018
News and Views
Links and Services
A study in this month's issue of the European Journal of Gastroenterology & Hepatology reviews the prevalence, infusion reactions, and response to anti-infliximab antibodies in IBD.
Infliximab is a chimeric monoclonal antibody directed against tumour necrosis factor-α.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors